Sort
10,766 grants matching “checkpoint inhibitor”
Therapeutic evaluation in ovarian and breast cancer GEM-GDA models
$1,106,205Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs
$1,103,955Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
DNA Repair in Human Cancer-Prone Genetic Diseases
$1,099,456Kenneth H Kraemer · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Novel Targets for Vaccine Therapy
$1,097,667Claudia Palena · Division Of Basic Sciences - Nci · ZIC · FY2018 · CA
Signal Transduction Events and the Regulation of Cell Growth
$1,097,545Jane B Trepel · Division Of Clinical Sciences - Nci · ZIC · FY2020 · CA
DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs
$1,094,655Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Leveraging DNA damage repair pathways as therapeutic targets in womens cancers
$1,092,801Jung-Min Lee · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Identification of genetic interactors of Brca2
$1,091,687Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Investigation of role of microbiota in development, progression and therapy of cancers
$1,088,170Amiran Dzutsev · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Center for Interventional Oncology
$1,086,388Bradford J Wood · Division Of Basic Sciences - Nci · ZID · FY2024 · CA
Signal Transduction Events and the Regulation of Cell Growth
$1,085,526Jane B Trepel · Division Of Clinical Sciences - Nci · ZIC · FY2023 · CA
Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy
$1,085,460Michael Demetriou · Glytr Therapeutics, Inc. · R42 · FY2025 · CA
UCSF Project 1
$1,085,090Trever G Bivona · University Of California, San Francisco · U54 · FY2017 · CA
Preclinical Development of First-in-Class GSTO1 Degraders for Colorectal Cancer
$1,084,396Nouri Neamati · University Of Michigan At Ann Arbor · R01 · FY2025 · CA
Proteogenomic Predictors of Recurrence in Non-small Cell Lung Cancer
$1,084,271Ramaswamy Govindan · Washington University · U01 · FY2022 · CA
Conserved Element DNA Vaccine
$1,083,056Barbara Felber · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Intravesical Immunotherapy of Spontaneous Canine Invasive Urothelial Carcinoma
$1,081,084David Zaharoff · North Carolina State University Raleigh · U01 · FY2025 · CA
Membrane-based vaccine with checkpoint blockade for triple negative breast cancer
$1,079,344Kamal V. Kannan · Metaclipse Therapeutics Corporation · R44 · FY2018 · CA
Vaccine and Drug Combination Therapy for Human Cancers
$1,076,634James Hodge · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Studies of the Function of Naturally Occurring and Adaptive T Regulatory Cells
$1,073,841Ethan Shevach · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
Vaccine strategies for HIVAIDS
$1,073,604Jay A Berzofsky · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Therapeutic evaluation in ovarian and breast cancer GEM-GDA models
$1,071,699Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
NYU BIOMARKER CLINICAL AND EPIDEMIOLOGIC CENTER
$1,068,291New York University School Of Medicine · U01 · FY2000 · CA
Targeting Pediatric Cancer Vulnerabilities
$1,066,178Kimberly Stegmaier · Dana-Farber Cancer Inst · R35 · FY2023 · CA
Targeting Pediatric Cancer Vulnerabilities
$1,065,492Kimberly Stegmaier · Dana-Farber Cancer Inst · R35 · FY2025 · CA